A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology

Background:

• Up to 30% of lymphangioleiomyomatosis (LAM) patients exhibit positive spirometry responses to bronchodilators (BDs).
• Previous research has not examined the effects of BDs on exercise outcomes, specifically dynamic hyperinflation (DH), in LAM patients.

Purpose of the Study:

• To investigate the impact of salbutamol on exercise outcomes, including dynamic hyperinflation (DH), in patients with lymphangioleiomyomatosis (LAM).

Main Methods:

• A randomized, double-blind, placebo-controlled, crossover trial involving 38 LAM patients.
• Comparison of inhaled salbutamol versus placebo, with assessments including pulmonary function tests and a cycle endurance test.
• Primary endpoint was the evaluation of DH via serial measurement of inspiratory capacity (IC) during exercise.

Main Results:

• Salbutamol showed a minor improvement in airway obstruction but did not significantly alter resting IC or air trapping.
• Only 18% of patients demonstrated a positive BD response based on spirometry criteria.
• BDs did not reduce DH or dyspnea, nor enhance exercise tolerance in the overall LAM population during submaximal exercise.

Conclusions:

• While salbutamol offers slight improvements in airway obstruction, it does not effectively reduce dynamic hyperinflation or improve exercise tolerance in LAM patients.
• The findings suggest limited therapeutic benefit of short-acting bronchodilators for exercise-related symptoms in LAM.